![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Gachon University Gil Medical Center |
---|---|
Information provided by: | Gachon University Gil Medical Center |
ClinicalTrials.gov Identifier: | NCT00478101 |
For cancer patients with inadequate pain relief, a switch to an alternative opioid is the preferred option for symptomatic improvement. However, multiple opioids are often simultaneously administered for anecdotal reasons.
The present study isdesigned to assess the analgesic profiles of two different strategies in chronic cancer pain: the opioid rotation from oxycodone to transdermal fentanyl and the combination of oral oxycodone and transdermal fentanyl.
Condition | Intervention | Phase |
---|---|---|
Advanced Solid Cancers |
Drug: oxycodone fentanyl |
Phase II |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Enrollment: | 2006 |
Study Start Date: | February 2006 |
Study Completion Date: | April 2007 |
Patients with uncontrolled cancer pain despite treatment of oral morphine equivalent ≥100 mg/d will be randomly assigned to oral opioids to transdermal fentanyl (rotation group) or oral oxycodone plus fentanyl (combination group). Patients answer a questionnaire that included pain severity (0 to 10) and interference items at baseline and after one week. Primary outcomes are change in pain score and treatment success.
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | GMO-SC-61 |
Study First Received: | May 22, 2007 |
Last Updated: | March 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00478101 History of Changes |
Health Authority: | Korea: Food and Drug Administration |
Pain |
Fentanyl Oxycodone Pain |